9966 — Alphamab Oncology Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$4.51bn
- HK$3.26bn
- CNY218.77m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | — |
Source: | ARS | ARS | ARS | ARS | |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Net Income/Starting Line | -833 | -428 | -412 | -326 | — |
Depreciation | |||||
Non-Cash Items | 608 | 46.3 | 13.3 | -69.3 | — |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -11.8 | 4.21 | 37.4 | 39.5 | — |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -225 | -347 | -321 | -300 | — |
Capital Expenditures | -171 | -90.8 | -158 | -130 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -483 | -1,433 | 732 | 980 | — |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -654 | -1,524 | 574 | 851 | — |
Financing Cash Flow Items | -60.3 | -32.5 | -14.9 | -19.3 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2,114 | 187 | 364 | -311 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1,234 | -1,683 | 618 | 266 | — |